Trial Profile
Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results of a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 studies assessed the the association of intrinsic subtypes and gene expression signatures with pathologic complete response and event-free survival presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 01 Oct 2021 Results (n=539) of an analysis assessing predictors of nodal pathologic complete response among patients from two clinical studies: CALGB40601 and CALGB40603 published in the Annals of Surgical Oncology
- 04 Jun 2019 Results of a combined analysis of CALGB40601 (Alliance) and PAMELA clinical trials, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.